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and Calcium Score for Major Adverse
Cardiac Events in Outpatients
Zhi-hui Hou, MD,* Bin Lu, MD,* Yang Gao, MD,* Shi-liang Jiang, MD,*
Yang Wang, MD,† Wei Li, MD,† Matthew J. Budoff, MD‡
Beijing, China; and Torrance, California
O B J E C T I V E S This study sought to evaluate the prognostic value of coronary artery calcium score
(CACS) and coronary computed tomography angiography (CTA) for major adverse cardiac events
(MACE).
B A C KG ROUND The prognostic value of CACS has been well described. Few studies use the rich
information of coronary CTA to predict future clinical outcomes and compare CACS with coronary CTA.
METHOD S We followed up 5,007 outpatients who were suspected of having coronary artery
disease (CAD) and who underwent cardiac CTA. Cardiac CT was assessed for CACS and the extent, the
location, the stenosis severity, and the composition of the plaque in coronary CTA. The endpoint was
MACE, deﬁned as composite cardiac death, nonfatal myocardial infarction, or coronary revascularization.
R E S U L T S Follow-up was completed in 4,425 patients (88.4%), with a median follow-up period of
1,081 days. At the end of the follow-up period, 363 (8.2%) patients had experienced MACE. Cumulative
probability of 3-year MACE increased across CT strata for CACS (CACS 0, 2.1%; CACS 1 to 100, 12.9%;
CACS 101 to 400, 16.3%; and CACS 400, 33.8%; log-rank p  0.001); for coronary CTA (no plaque 0.8%,
nonobstructive disease 3.7%, 1-vessel disease 27.6%, 2-vessel disease 35.5%, and 3-vessel disease 57.7%;
log-rank p  0.001); and for characteristics of the plaques (5.5% for calciﬁed plaque, 22.7% for
noncalciﬁed plaque, and 37.7% for mixed plaque; log-rank p  0.001). The area under the receiver-
operating characteristic curves showed the incremental value of CACS and coronary CTA for predicting
MACE: 0.71 for clinical risk factors, which improved to 0.82 by adding CACS and further improved to 0.93
by adding coronary CTA (both p  0.001).
CONC L U S I O N S The CACS and coronary CTA ﬁndings have prognostic value and have incremental
value over routine risk factors for MACE, and coronary CTA is superior to CACS. Cardiac CT seems to be
a promising noninvasive modality with signiﬁcant prognostic value. (J Am Coll Cardiol Img 2012;5:
990–9) © 2012 by the American College of Cardiology Foundation
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991T
he multivariable statistical models of tradi-
tional coronary heart disease risk factors, such
as Framingham risk score, are widely recom-
mended for coronary risk stratification among
ndividual patients (1,2). But the models have
imitations in their ability to discriminate persons
ho will or will not experience coronary artery
isease (CAD) (3). Since the first report of the use
f contrast-enhanced computed tomography (CT)
See page 1000
to obtain noninvasive coronary angiograms in 1995
(4), cardiac CT has evolved to become a highly
accurate method in the diagnosis of CAD, compa-
rable to conventional invasive coronary angiography
(5). Given the uncertainty of current risk factors
predictive models, a recommended approach to
improve risk prediction over the traditional risk
factors is coronary artery calcium score (CACS),
and the prognostic value of CACS has been well
described (6,7). The CONFIRM (Coronary CT
Angiography Evaluation for Clinical Outcomes: An
International Multicenter Registry) study showed
that nonobstructive and obstructive CAD by coro-
nary computed tomography angiography (CTA) are
associated with higher rates of mortality, whereas
absence of CAD is associated with a very favorable
prognosis (8). Although coronary CTA can give us
rich information regarding plaque burden, few
studies have evaluated that information to predict
future clinical outcomes and compare with the
prognostic power of CACS.
M E T H O D S
Patient selection. We evaluated 6,477 consecutive
atients between January 2007 and August 2008 in
u Wai Hospital who underwent cardiac CT using
64-slice multidetector CT scanner. All of these
atients were referred for cardiac CT studies by
heir cardiologists. The coronary CTA was per-
ormed because of symptoms of chest pain, to
xclude coronary disease in patients carrying 1 or
ore risk factors or electrocardiographic abnormal-
ties, or to evaluate prior revascularization. For the
resent study, we excluded subjects with a history of
oronary revascularization (percutaneous coronary in-
ervention [PCI], n  991), coronary artery bypass
raft surgery (CABG) (n  263), history of acute
yocardial infarction (MI) (n  54), inadequate
mage quality because of motion artifacts or inade-
uate contrast concentration (n 49), or having other Teart diseases (cardiomyopathy n  55, valvular heart
isease n  15, congenital heart disease n  43). In
total, 5,007 patients were enrolled (Fig. 1).
Data acquisition. Scans were performed using a 64-
ow spiral CT scanner (Light Speed VCT, GE
ealthcare, Milwaukee, Wisconsin). Patients with
pre-scan heart rate of 70 beats/min or higher were
iven 25 mg to 50 mg of metoprolol (Selokeen,
straZeneca, Zoetermeer, the Netherlands) orally
h before scanning. First, patients underwent
onenhanced prospective electrocardiography
ECG)-gated sequential scan to measure CACS.
hereafter, coronary CTA was performed using
etrospective ECG gating with ECG-based tube
urrent modulation. A double-head power injector
Stellant, Medrad, Pittsburgh, Pennsylva-
ia) was used to inject contrast media
hrough a 20G trocar in an antecubital
ein. A test bolus (10 ml contrast agent
ollowed by a 20-ml saline flush) with
njection rate of 5 ml was used to deter-
ine the timing of scan delay and image
cquisition time. Depending on patient
eight, iohexol 350 mgI/ml (Omnipaque
50, GE Healthcare) or iopromide 370
gI/ml (Ultravist 370, Bayer-Schering
harma, Berlin, Germany) was injected at
speed of 4 to 5.5 ml/s. The main
canning parameters were as follows: 64
etectors; 0.625 mm individual detector
idth; 350 ms gantry rotation time; 120
V tube voltage; ECG-modulated tube
urrent ranged from 200 to 550 mA (the
ube current was 550 mA during 40% to
0% RR interval when diagnostic image
uality was required, and remained at 200
A during the other phases of the RR
nterval); 0.16 to 0.22 pitch; 400 mm table
eed/rotation; 200 to 250 mm field of view.
Image analysis. All the scans were retrospectively
nalyzed on the workstation (Deep Blue, ADW4.3,
E Healthcare). Calcium was defined as the pres-
nce of at least 3 contiguous pixels with a density
130 HU. The total calcium burden in the coro-
ary arteries was quantified by the scoring algo-
ithm proposed by Agatston et al. (9), and pre-
efined calcium score categories (0, 1 to 100, 101 to
00, and400) were used (10). The coronary artery
ree was segmented according to the modified
merican Heart Association classification, and
hese segments were subsequently investigated for
he presence and characteristics of coronary plaques.
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992if the patient had 50% diameter stenosis on the
longitudinal images. We evaluated the plaque ex-
tent and stenosis rate by summing the number of
epicardial vessels with significant stenosis (no
plaque, no obstructive, 1-vessel disease, 2-vessel
disease, 3-vessel disease). Coronary plaques were
classified as calcified (composed exclusively of high-
density material 130 HU), noncalcified (com-
posed exclusively of material having density 130
HU), and mixed (having components of both cal-
cified and noncalcified plaques) (11). At patient-
level analysis, if 1 type of plaque was present, the
characteristic of the most stenotic plaque was re-
corded for statistical analysis.
CAD risk factors assessment. The conventional cor-
nary risk factors such as obesity, cigarette smoking,
ypertension, hypercholesterolemia, diabetes melli-
us, and family history were assessed. Obesity was
efined as body mass index 30 kg/m2. Smoking
as defined as any cigarette smoking within 1 year
f the cardiac CT. Hypertension was defined as a
reviously established diagnosis, systolic blood
ressure 140 mm Hg, diastolic blood pressure
90 mm Hg, or antihypertensive medication use.
ypercholesterolemia was defined according to the
ational Cholesterol Education Panel guidelines or
y the current use of lipid-lowering medication
12). Diabetes mellitus was defined as a previously
stablished diagnosis, insulin or oral hypoglycemic
herapy, fasting glucose of 126 mg/dl, or nonfast-
ng glucose of 200 mg/dl. Family history of CAD
as defined as MI, coronary revascularization, or
6477 Cons
und
49 p
inade
500
Exclusion criteria
Finally enrolled
95.4% by
telephone call
2.2% by
physicians
2.4
hospita
4425 (88.4%) complete
follow-up
1308 patients with history
of MACE
Figure 1. Flow Chart of the Follow-Up
In all, 6,477 consecutive patients who underwent cardiac computed
pital were evaluated. For the present study, 5,007 patients were ﬁn
puted tomography; MACE  major adverse cardiac events.udden cardiac death for father55 years-of-age orother 65 years-of-age. Typical angina was de-
ned as a combination of: 1) discomfort in the
nterior chest, neck, shoulders, jaw, or arms; 2)
recipitated by physical exertion or emotional
tress; and 3) relieved by rest or nitroglycerin
ithin minutes. Atypical angina was defined as
hest pain with 2 of these 3 factors, and nonangi-
al chest pain was defined as chest pain with 2
f these 3 factors (13).
Follow-up. Risk factors and MACE information
was obtained from patient telephone interviews,
contact with the patients’ physicians, and hospital
records. A standard questionnaire was used during
the telephone interview. MACE included any of
the following: 1) cardiac death; 2) new acute MI; or
3) coronary revascularization (PCI and CABG).
Hard MACE included: 1) cardiac death or 2) new
acute MI. Cardiac death was defined as death due
to acute MI, ventricular arrhythmias, refractory
heart failure, or cardiogenic shock. We reviewed all
available data to determine whether a cardiac etiol-
ogy was the immediate cause of death. New acute
MI was defined based on the criteria of typical chest
pain, elevated cardiac enzyme levels, and typical
alterations of ECG. We contacted patients’ physi-
cians and hospital records (including ECG, cardiac
enzyme levels, and other available data) to adjudi-
cate all events.
The decisions to submit patients to revascular-
ization were made by referring physicians, taking
into account all available information and patient
preferences. Revascularization procedures within 60
tive patients
ent CT
nts with
te image
tients
ords
67.9% can’t be
connected
32.1% no accurate
information
582 (11.6%) incomplete
follow-up
113 patients with
other heart diseases
ography between January 2007 and August 2008 in Fu Wai Hos-
enrolled, and 4,425 patients were ﬁnally analyzed. CT  com-ecu
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993gered by the scan and were not considered events.
Using this 60-day landmark for analysis, early
coronary CTA-driven events (referring physicians
were likely to include coronary CTA findings in
management decisions) were excluded. Because
most patients were symptomatic and undergoing
evaluation for suspected CAD, it was considered
ethical and necessary to make CT findings known
to referring physicians. When a patient experienced
1 MACE, the first event was chosen. When 2
MACE occurred simultaneously, the worse event
was chosen (death worse than MI, MI worse than
revascularization). An adjudication outcome panel
of 2 physicians reviewed the patient data forms and
verified by review of medical records to determine
whether a patient had MACE during the follow-up
period. The outcome panel was blinded to the
findings of the cardiac CT. Disagreement was
resolved by consensus, which included an additional
senior cardiologist. If a patient could not be con-
tacted, that patient was considered lost to follow-
up. Three attempts were made using the patient’s
direct phone number in 1 week. If we were unsuc-
cessful or if the patient could not provide accurate
information, that patient was tabulated as lost to
follow-up.
Statistical methods. All the statistical analyses were
onducted by a specialist of medical statistics and
erformed using SPSS version 17.0 for Windows
SPSS Inc., Chicago, Illinois). For descriptive anal-
sis, continuous variables were represented as the
ean  SD, and categorical variables were repre-
ented as percentages. Variables were compared
ith chi-square statistic for categorical variables and
y t test for continuous variables. Cumulative event
Table 1. Baseline Characteristics for All Patients
Overall
(N  4,425)
Age, yrs 59.6 11.3
Male 2,748 (62.1)
Obesity 1,065 (24.1)
Hypertension 2,538 (57.4)
Diabetes mellitus 640 (14.5)
Dyslipidemia 1,220 (27.6)
Family history of CAD 1,554 (35.1)
Smoking 1,367 (30.9)
Chest pain
Typical angina 266 (6.0)
Atypical angina 708 (16.0)
Nonanginal chest pain 2,079 (47.0)
Values are mean  SD or n (%).
CAD  coronary artery disease; MACE  major adverse cardiac event.ates as stratified by CT features were estimated
sing the product-limit (Kaplan-Meier) methods
nd log-rank test. We fitted Cox proportional
azards models to estimate the unadjusted hazard
atio (HR) of all variables and evaluate the prog-
ostic value of risk factors, risk factors plus CACS,
nd risk factors plus CACS plus coronary CTA for
redicting MACE. The area under the receiver-
perating characteristic (ROC) curve was deter-
ined to evaluate the prognostic discriminatory
apacity for predicting MACE for each Cox model.
he incremental prognostic value of adding CACS
nd coronary CTA beyond that of risk factors was
etermined by comparing the global chi-square
alue of the models. A 2-sided p value 0.05 was
onsidered statistically significant.
R E S U L T S
In all, 582 (11.6%) patients were lost follow-up
(395 patients could not be contacted, and 187
patients could not provide accurate information).
The remaining 4,425 patients (mean age 59.6 
11.3 years; 62.1% men) were finally analyzed. The
cohort was followed up for a median of 1,081 days
(quartile 1  960 days, quartile 3  1,192 days).
The majority of the patients (n  4,223, 95.4%)
were followed up by a standardized telephone call.
Others (n  202, 4.6%) were followed up by
contact with the patients’ physicians (n 98, 2.2%)
r hospital records (n  104, 2.4%). Patients
resented with nonanginal chest pain (n  2,079,
7.0%), atypical angina (n  708, 16.0%), and
ypical angina (n  266, 6.0%). Patients with
ACE had more coronary risk factors (Table 1).
MACE
(n  363)
No MACE
(n  4,062) p Value
63.6 10.8 59.0 11.2 0.001
258 (71.1) 2,490 (61.3) 0.001
90 (24.8) 975 (24.0) 0.736
261 (71.9) 2,277 (56.1) 0.001
91 (25.1) 549 (13.5) 0.001
102 (28.0) 1,118 (26.5) 0.814
141 (38.8) 1,413 (34.8) 0.071
131 (36.1) 1,236 (30.4) 0.007
30 (8.3) 236 (5.8) 0.059
62 (17.1) 646 (16.0) 0.558
178 (49.0) 1,901 (46.8) 0.413
w
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994Cardiac CT ﬁndings. In all, 2,536 (57.3%) subjects
ere noted to have no plaque within the coronary
rteries. Additionally, only nonobstructive plaque
as noted in 1,021 (23.1%) subjects. Among 868
19.6%) patients with significant stenosis, 1-vessel
isease, 2-vessel disease, and 3-vessel disease were
oted in 438 (9.9%), 233 (5.3%), and 197 (4.5%),
espectively. Three hundred ninety-one (8.8%) pa-
ients had left main (LM) disease, and 78 (1.8%)
ad occlusion disease. Calcified plaque, noncalcified
Table 2. Baseline Characteristics and Rates of Obstructive
Coronary Segments for Each Segment in Follow-Up Subjects
and Lost to Follow-Up Subjects
Follow-Up
(n  4,425)
Lost to
Follow-Up
(n  582) p Value
Age, yrs 59.6 11.3 58.9 10.9 0.698
Male 2,748 (62.1) 367 (63.1) 0.655
Obesity 1,065 (24.1) 132 (22.7) 0.461
Hypertension 2,538 (57.4) 312 (53.6) 0.086
Diabetes mellitus 640 (14.5) 76 (13.1) 0.363
Dyslipidemia 1,220 (27.6) 175 (30.1) 0.206
Family history of CAD 1,554 (35.1) 186 (32.0) 0.132
Smoking 1,367 (30.9) 198 (34.0) 0.126
Chest pain
Typical angina 266 (6.0) 30 (5.5) 0.410
Atypical angina 708 (16.0) 105 (18.0) 0.209
Nonanginal chest pain 2,079 (47.0) 250 (43.0) 0.067
LM 391 (8.8) 48 (8.2) 0.637
LAD 724 (16.4) 108 (18.6) 0.181
Proximal 442 (11.1) 70 (12.0) 0.127
Mid or distal 212 (5.2) 32 (5.5) 0.456
Diagonal 70 (1.6) 6 (1.0) 0.307
LCX 334 (7.5) 43 (7.4) 0.891
Proximal 121 (2.7) 15 (2.6) 0.826
Mid or distal 63 (1.4) 7 (1.2) 0.669
OM 150 (3.4) 21 (3.6) 0.785
RCA 434 (9.8) 55 (9.5) 0.785
Proximal 231 (5.2) 26 (4.5) 0.439
Mid or distal 203 (4.6) 29 (5.0) 0.670
Values are mean  SD or n (%).
CAD  coronary artery disease; LAD  left anterior descending; LCX  left
circumﬂex artery; LM  left main; OM  obtuse marginal; RCA  right
coronary artery.
revalence of Coronary Artery Disease and MACE in Men
n
Total
(N  4,425)
Men
(n  2,748)
Women
(n  1,677) p Value
1,889 (42.7) 1,235 (44.9) 654 (39.0) 0.001
stenosis 868 (19.6) 580 (21.1) 288 (17.2) 0.001
363 (8.2) 258 (9.4) 105 (6.3) 0.001
(%).
ajor adverse cardiac events.laque, and mixed plaque were noted in 1,021
23.1%), 183 (4.1%), and 685 (15.5%) subjects,
espectively. CACS  0 was noted in 2,785
62.9%) subjects; CACS 1 to 100, CACS 101 to
00, and CACS 400 were noted in 813 (18.4%),
83 (10.9%), and 344 (7.8%) subjects, respectively.
here were no significant differences in the rates of
bstructive disease per segment and baseline char-
cteristics between the follow-up group and lost to
ollow-up group (Table 2).
Follow-up. At the end of the study, 40 cardiac
deaths, 87 new acute MI, and 371 coronary revas-
cularizations (319 PCI and 52 CABG) were found.
During the first 60 days, MACE developed in 156
patients (1 cardiac death, 20 new acute MI, 122
PCI, and 13 CABG). After eliminating revascular-
izations within 60 days, 363 (8.2%) patients had
experienced MACE. The prevalence of any plaque,
significant stenosis, and MACE was significantly
higher among men than among women (Table 3).
Figure 2 depicts the Kaplan-Meier estimates of
the cumulative probability of MACE as stratified
by CT findings; Table 4 provides the probability of
events at various time points. The probability of
3-year MACE increased significantly across the
strata of CACS categories (2.1% for patients with
CACS  0, 12.9% for patients with CACS 1 to
100, 16.3% for patients with CACS 101 to 400, and
33.8% for patients with CACS400; log-rank p
0.001), coronary CTA categories (0.8% for no-
plaque patients, 3.7% for patients with only nonob-
structive plaque, 27.6% for 1-vessel disease patients,
35.5% for 2-vessel disease patients, and 57.7% for
3-vessels patients; log-rank p  0.001), and the
characteristics of the plaques (5.5% for calcified
plaque, 22.7% for noncalcified plaque, and 37.7%
for mixed plaque; log-rank p  0.001).We also
found the probability of MACE increased signifi-
cantly across patients with LM disease and occlu-
sive disease.
Figure 3 depicts CACS and several coronary
CTA findings that demonstrated significant asso-
ciations with MACE. An unadjusted analysis of
MACE is presented in Table 5. Table 6 gives the
incremental value of adding cardiac CT beyond
that of the risk factors for predicting MACE.
The discriminatory capacity for predicting MACE
improved from an area under the ROC curve of 0.71
with the risk factors alone to 0.82 when CACS was
added (p  0.001), which further improved to 0.93
with the addition of coronary CTA (p  0.001)Table 3. P
and Wome
Any plaque
Signiﬁcant
MACE
Values are n(Fig. 4).
e
a
c
n
e
n
C
quartile 3  1,192 days). MACE  major adverse cardiac events.
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995D I S C U S S I O N
The strength of our study is that it provides
prognostic data from a large cohort, as stratified by
cardiac CT findings for MACE. We also recognize
that incomplete follow-up may result in underre-
porting of MACE. However, no significant differ-
ence was found between subjects with follow-up
and those lost to follow-up (p  0.05 for all
measures). Women in our study had lower rates of
both obstructive CAD and MACE in contrast to
their male counterparts.
Prognostic value of CACS. The prognostic value of
CACS over clinical and laboratory data has been
previously demonstrated in a large cohort of pa-
tients (14,15). As previous studies have shown, no
or very few patients with CACS  0 had events at
follow-up, whereas patients with CACS 400
largely had significant CAD with a very high
incidence of events. Michael et al. (16) noted that
CACS  0 predicts excellent survival, with 10-year
event rates of approximately 1% (0.1% per year),
and the HR for all-cause mortality among patients
with CACS of 101 to 400 and 400 compared
with CACS  0 was 5.56 (95% confidence interval
[CI]: 4.27 to 7.21) and 9.65 (95% CI: 7.46 to 12.5),
respectively. We similarly found the probability of
3-year MACE was 33.8% for CACS 400 and
only 2.1% for CACS  0 (1% per year). The HR
for patients with CACS of 101 to 400 and 400
compared with patients with CACS  0 were 9.21
(95% CI: 6.50 to 13.05) and 22.22 (95% CI: 16.08
to 30.71), respectively, modestly higher than the
prior study, which only evaluated mortality (16).
Previous studies have demonstrated that CACS
assessment combined with risk factors among
asymptomatic adults provides prognostic informa-
tion superior to either method alone, and the
combined approach can more accurately guide pri-
mary preventive strategies for patients with CAD
risk factors (17). We found with the addition of
CACS to risk factors, the area under the ROC
curves improved from 0.71 to 0.82 (p  0.001),
indicating the incremental prognostic value of
CACS over clinical risk factors in this population.
Prognostic value of coronary CTA. Several groups
xamined the prognostic value of coronary CTA
nd showed that normal coronary CTA findings
onfer an excellent prognosis and abnormal coro-
ary CTA findings are associated with adverse
vents (18–20). The CONFIRM study confirmed
onobstructive and obstructive CAD by coronaryNo plaque
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Figure 2. Kaplan-Meier Curves of MACE as Stratiﬁed by
Coronary CTA Features
(A) Coronary computed tomography angiography (CTA) catego-
ries stratiﬁed into no plaque (red line), no obstructive (yellow
line), 1-vessel disease (blue line), 2-vessel disease (green line),
and 3-vessel disease (purple line). (B) Coronary artery calcium
score (CACS) categories stratiﬁed into CACS  0 (red line), CACS
1 to 100 (yellow line), CACS 101 to 400 (blue line), and CACS
400 (green line). (C) The characteristics of the plaques catego-
ries stratiﬁed into calciﬁed plaque (red line), noncalciﬁed plaque
(yellow line), and mixed plaque (blue line). The cohort was fol-
lowed up for a median of 1,081 days (quartile 1  960 days,TA are associated with higher rates of mortality
2.
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996(8). In those studies, CAD severity and coronary
atherosclerosis predicted all-cause mortality. How-
ever, those studies were not able to stratify accord-
ing to cause of death nor did they track other
MACE such as cardiac death and new acute MI.
Further, few studies have used plaque information
from coronary CTA to predict future clinical out-
Table 4. Kaplan-Meier Cumulative Probability of MACE at 60 Da
Computed Tomography Findings
N  4,425
CACS  0 2,785 (62.9)
CACS 1–100 813 (18.4)
CACS 101–400 483 (10.9)
CACS 400 344 (7.8)
No plaque 2,536 (57.3)
No obstructive 1,021 (23.1)
1-vessel disease 438 (9.9)
2-vessel disease 233 (5.3)
3-vessel disease 197 (4.5)
No LM disease 4,034 (91.2)
LM disease 391 (8.8)
No occlusion disease 4,347 (98.2)
Occlusion 78 (1.8)
Calciﬁed plaque 1,021 (23.1)
Noncalciﬁed plaque 183 (4.1)
Mixed plaque 685 (15.5)
Values are n (%).
CACS  coronary artery calcium score; other abbreviations as in Tables 1 and
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Figure 3. Unadjusted Cardiac CT Findings for Predicting MACE
Computed tomography (CT) strata for coronary artery calcium score
(CTA) ﬁndings demonstrated signiﬁcant associations with major adversecomes. Our results expand on previous literature by
using 64-slice coronary CTA, capturing MACE,
highlighting the incremental value of coronary
CTA findings, such as the extent (the number of
obstructive major epicardial coronary arteries), the
location (LM disease), occlusive disease, and the
composition of the plaque (calcified, noncalcified,
1 Year, and 3 Years as Stratiﬁed by
MACE (Probability)
60 Days 1 Year 3 Years
3 (0.1) 37 (1.4) 56 (2.1)
10 (1.5) 67 (8.6) 103 (12.9)
1 (0.2) 47 (9.9) 74 (16.3)
7 (2.2) 65 (18.9) 113 (33.8)
0 (0) 8 (0.4) 14 (0.8)
1 (0) 14 (1.6) 33 (3.7)
8 (1.9) 75 (17.7) 119 (27.6)
6 (2.7) 53 (22.9) 82 (35.5)
6 (3.3) 66 (33.7) 98 (57.7)
13 (0.4) 110 (2.9) 181 (4.9)
8 (2.1) 106 (27.5) 165 (42.5)
17 (0.5) 195 (4.5) 307 (7.3)
4 (5.1) 21 (26.9) 39 (50.1)
4 (0.4) 29 (2.9) 54 (5.5)
0 (0) 31 (16.9) 40 (22.7)
14 (2.0) 148 (22.6) 238 (37.7)
10191817161
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997or mixed). We found the probability of 3-year
MACE increased significantly across all of the
strata of coronary CTA categories, especially for the
extent of obstructive disease (the probability of
3-year MACE was 57.7% for 3-vessel disease but
only 0.8% for patients with no plaque). Nonob-
structive lesions are frequently the culprits in acute
coronary syndromes and sudden cardiac death (21).
We found the probability of 3-year MACE was
3.7% for patients with nonobstructive lesions, sim-
ilar to, but a little higher than found by a previous
study (2.1%) (22). Most likely, that represents the
use of different endpoints, as the prior study only
evaluated cardiac death. A meta-analysis showed coro-
nary CTA has excellent sensitivity (99%) and negative
likelihood ratio (0.008) to exclude future coronary clinical
Table 5. Unadjusted Risk Factors and Cardiac Computed Tomog
Risk Factors
All MACE
HR (95% CI)
Age 1.04 (1.03–1.06)
Male 2.06 (1.62–2.62)
Diabetes mellitus 1.56 (1.20–2.03)
Hypertension 1.60 (1.221–2.09)
Dyslipidemia 1.01 (0.82–1.22)
Smoking 1.62 (1.21–2.12)
Obesity 1.10 (0.79–1.35)
Family history 1.27 (1.01–1.61)
CACS  0 (reference) 1.00
CACS 1–100 7.18 (5.16–10.00)
CACS 101–400 9.21 (6.50–13.05)
CACS 400 22.22 (16.08–30.71)
No CAD* (reference) 1.00
One-vessel disease 28.99 (20.86–40.38)
Two-vessel disease 40.86 (28.69–58.19)
Three-vessel disease 75.20 (53.53–105.64)
No LM disease (reference) 1.00
LM disease 15.64 (12.60–19.42)
No occlusion (reference) 1.00
Occlusion 15.56 (10.89–22.22)
Calciﬁed plaque (reference) 1.00
Noncalciﬁed plaque 5.30 (3.67–7.65)
Mixed plaque 9.54 (7.21–12.64)
*No coronary artery disease (CAD) means no plaque plus no obstructive.
CI  conﬁdence interval; HR  hazard ratio; NA  not applicable; other ab
Table 6. Incremental Predictive Value of Cardiac Computed Tom
AUC 95% CI
Risk factors 0.71 0.68–0.74
Risk factors  CACS 0.82 0.80–0.85
Risk factors  CACS  coronary CTA 0.93 0.92–0.95AUC  area under the curve; CI  conﬁdence interval; CTA  computed tomograpevents when pooled across the 9,592 patients with
symptoms of possible angina in 17 studies over a median
20-month follow-up duration (23). The negative predic-
tive value of our study was 99.4%, and the negative
likelihood ratio was 0.006, similar to the results of a
prior meta-analysis (23). Coronary CTA could eval-
uate the characteristics of the plaques, which add
strength to coronary CTA compared with invasive
coronary arteriography. We found the probability
of 3-year MACE was significantly higher for
noncalcified and mixed plaque than for calcified
plaque. The current concept is that soft, lipid-
filled plaques are most vulnerable, leading to
subsequent clinical events (24). Acknowledging
the potential value of plaque location and total
occlusion, we also examined LM disease and
hy Findings for Predicting All MACE and Hard MACE
p Value
Hard MACE
HR (95% CI) p Value
0.001 1.01 (1.00–1.04) 0.042
0.001 2.00 (1.23–2.34) 0.001
0.001 1.21 (1.07–1.92) 0.003
0.001 1.42 (1.12–2.00) 0.012
0.621 1.01 (0.73–1.12) 0.745
0.001 1.22 (1.14–2.02) 0.001
0.349 1.02 (0.71–1.22) 0.547
0.044 1.21 (1.00–1.44) 0.048
NA 1.00 NA
0.001 6.90 (3.97–12.00) 0.001
0.001 8.33 (4.62–15.00) 0.001
0.001 20.97(12.22–37.31) 0.001
NA 1.00 NA
0.001 17.83 (10.43–30.46) 0.001
0.001 20.59 (11.32–37.45) 0.001
0.001 56.81 (33.95–95.06) 0.001
NA 1.00 NA
0.001 13.13 (9.22–18.69) 0.001
NA 1.00 NA
0.001 13.55 (8.68–19.21) 0.001
NA 1.00 NA
0.001 3.01 (1.34–4.24) 0.001
0.001 4.23 (1.58–7.57) 0.001
iations as in Tables 1, 2, and 4.
raphy Findings Beyond That of Risk Factors
p Value
Global Chi-Square
Value
Model Comparisons
p Value
0.001 172.07 N/A
0.001 636.26 0.001
0.001 2090.26 0.001rapoghy angiography; other abbreviations as in Tables 4 and 5.
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998occlusive disease; the unadjusted HRs for pre-
dicting MACE were 15.64 and 15.56, respec-
tively. We found that the addition of plaque
characterization with coronary CTA to risk fac-
tors and CACS led to significant improvement of
the area under the ROC curves, from 0.82 to 0.93
(p  0.001).
Comparing prognostic value of CACS and coronary
CTA. In the study by Kwon et al. (25), the event-
ree survival was excellent for patients with CACS 0.
hus, despite the incremental prognostic value of
oronary CTA in the overall patient population, for
he subset of patients with a calcium score of 0,
onger and higher radiation dose protocols seems
nappropriate. However, Henneman et al. (26)
oted a 30% prevalence of obstructive CAD as seen
y coronary CTA in patients with CACS  0
resenting to the emergency department with
ighly suspected acute coronary syndrome. The
alue of CACS  0 depends upon the pre-test
ikelihood of patients. For our outpatients, we
ound 56 patients with CACS  0 had events in 3
ears, whereas only 14 patients with normal coro-
ary CTA had events in 3 years. Thus, among
utpatients, coronary CTA seems appropriate for
0.0 0.2 0.4 0.6 1.00.8
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Figure 4. ROC Curves of 3 Models
Receiver-operating characteristic (ROC) curves show the incre-
mental value of coronary artery calcium score (CACS) and coro-
nary computed tomography angiography (CTA): risk factors only
(area under the curve [AUC] 0.71; 95% conﬁdence interval [CI]:
0.68 to 0.74, p  0.001 [blue line]). Risk factors plus CACS (AUC
0.82; 95% CI: 0.80 to 0.85, p  0.001 [yellow line]), and risk fac-
tors plus CACS plus coronary CTA (AUC 0.93; 95% CI: 0.92 to
0.95, p  0.001 [red line]). Green line indicates reference line.hat it is important to keep in mind that even in the
bsence of coronary artery calcification, relatively
ore events occur among patients with higher risk,
specially persons with diabetes mellitus and smok-
ng history. The positive predictive value of our
tudy for CACS400 was 32.8%, which was better
han 1-vessel disease (27.1%), similar to 2-vessel
isease (35.2%), and lower than 3-vessel disease
49.7%). Few patients with heavy coronary artery
alcifications had no noncalcified plaque. Although
eavy coronary artery calcifications limits the accurate
valuation of the segment, for the vessel level or
atient level evaluation, the limitations were fewer
27). Furthermore, we found the probability of 3-year
ACE was significantly higher for noncalcified and
ixed plaque than for calcified plaque. The discrim-
natory capacity for predicting MACE further im-
roved when coronary CTA was added beyond risk
actors and CACS, indicating that coronary CTA has
ncremental value over routine risk factors and CACS.
Study limitations. This is a study from a single
center, and most of our patients were symptomatic,
which may limit the generalizability of our results to
similar care settings and the general population.
Bias is inevitable, for blinding of CT results may
not be realistic because of the advanced use of
cardiac CT in clinical practice, and because of the
clinical nature of the study, in which cardiac CT
was ordered to assist with management.
Another potential weakness is the self-reporting of
risk factors. Data gathered by self-report is limited by
patient recall, and thus subject to recall bias. The lack
of a continuous risk variable may decrease the preci-
sion of point estimates of risk, but the use of categor-
ical risk factor data has been validated as an approach
to clinical risk stratification (28).
C O N C L U S I O N S
The CACS and coronary CTA findings have prognostic
value and have incremental value over routine risk factors
for MACE. In this outpatient population, coronary
CTA is superior to CACS and traditional risk factors.
Cardiac CT seems to be a promising noninvasive mo-
dality with significant prognostic value.
Reprint requests and correspondence: Dr. Bin Lu, Cardio-
ascular Institute and Fu Wai Hospital, Chinese Acad-
my of Medical Sciences & Peking Union Medical
ollege, 167 Bei Li Shi Street, Xi-Cheng District,those with CACS  0. Michael et al. (16) noted Beijing 100037, China. E-mail: blu@vip.sina.com.
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